Development of Recombinant Canarypox Viruses Expressing Immunogens

Abstract

Canarypox viruses (CNPV) are excellent candidates to develop recombinant vector vaccines due to both their capability to induce protective immune responses and their incompetence to replicate in mammalian cells (safety profile). In addition, CNPV and the derived recombinants can be manipulated under biosafety level 1 conditions. There is no commercially available system to obtain recombinant CNPV; however, the methodology and tools required to develop recombinant vaccinia virus (VV), prototype of the Poxviridae family, can be easily adapted. This chapter provides protocols for the generation, plaque isolation, molecular characterization, amplification and purification of recombinant CNPV.

NF-κB as an Important Factor in Optimizing Poxvirus-Based Vaccines against Viral Infections

“…The present status of clinical trials employing VACV against viral diseases is shown in Table 1. Other poxviruses that can be used as vaccine vectors belong to Avipoxvirus [44,45], Capripoxvirus [46], Leporipoxvirus [47], Parapoxvirus [48], and Suipoxvirus [49] genera. Abbreviations: Ad, adenovirus; Ad26, Ad serotype 26; Ad26.HPV16, Ad26 HPV16 vaccine; Ad26.HPV18, Ad26 HPV18 vaccine; Ad26.Mos.HIV, Ad26-mosaic-HIV vaccine; Ad26.Mos4.HIV, Ad26-mosaic 4-HIV vaccine; Ad26.ZEBOV, human Ad26 expressing the Ebola virus Mayinga variant gp; AIDS, acquired immune deficiency syndrome; ATI, analytical treatment interruption; bNAbs, broadly neutralizing HIV-1 antibodies; ChAd, Chimpanzee adenovirus; ChAd155, ChAd serotype 155; ChAd155-hIi-HBV, ChAd HBV vaccine; ChAd3-hliNSmut, ChAd3 encoding NSmut linked to hli; ChAdOx1, replication-deficient ChAd vector derived from isolate Y25; ChAdOx1.HTI, ChAdOx1 expressing HTI; ChAdV63, ChAd serotype 63; ChAdV63.HIVconsv, ChAdV63 expressing HIVconsv; CMV, cytomegalovirus; DNA.HTI, plasmid DNA expressing HTI; gp, glycoprotein; gp140 DP, gp140 drug product; GS-9620, vesatolimod; HBc, hepatitis B core antigen; HBc-HBs/AS01B-4, HBV vaccine; HBs, hepatitis B surface antigen; HBV, hepatitis B virus; HCT, hematopoietic cell transplantation; HIV, human immunodeficiency virus; HIV-1, HIV type 1; HIVcons, HIV conserved antigenic regions; hli, human invariant chain; HPV, human papillomavirus; HPV16/18, human papillomavirus type 16/18; HTI, HIVACAT T cell immunogen; IL-12, interleukin-12; M1, matrix protein; MenACWY, meningococcal ACWY-tetanus toxoid conjugate vaccine; MPXV, monkeypox virus; MVA, modified vaccinia virus Ankara; MVA.HIVconsv, MVA expressing HIVconsv; MVA.HPV16/18, MVA HPV16/18 vaccine; MVA.HTI, MVA expressing HTI; MVA.tHIVconsv3, MVA.tHIVconsv4, MVA-based T-cell vaccines expressing novel HIV-1 immunogens; MVA62B, MVA component encoding HIV-1 Gag, protease, reverse transcriptase, and envelope protein gp160; MVA-BN, MVA-Bavarian Nordic; MVA-BN-Filo, MVA-BN-Filo vector; MVA-HBV, MVA HBV vaccine; MVA-hliNSmut, MVA encoding NSmut linked to hli; MVA-mosaic, MVA mosaic HIV vaccine; MVA-NP + M1, MVA encoding NP and M1; NP, nucleoprotein; NSmut, HCV nonstructural immunogen; p24CE + p55 gag , DNA vaccines expressing p24CE and p55 gag immunogens; rVSV∆G-ZEBOV-GP, recombinant VSV-Zaire Ebola virus gp; TLR9, Toll-like receptor 9; VRC07, 10-1074, anti-HIV-1 bNAbs; VSV, vesicular stomatitis virus.…”